Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1106Carcinoma, Renal Cell 412Urinary Bladder Neoplasms 280Kidney Neoplasms 177Neoplasm Metastasis 134Neoplasms 132Carcinoma, Non-Small-Cell Lung 109Carcinoma, Transitional Cell 108Breast Neoplasms 94Melanoma 90Ovarian Neoplasms 70Lung Neoplasms 67Colorectal Neoplasms 58Pancreatic Neoplasms 49Sarcoma 48Wilms Tumor 41Uterine Cervical Neoplasms 37Head and Neck Neoplasms 37Stomach Neoplasms 36Testicular Neoplasms 33Non-Muscle Invasive Bladder Neoplasms 33Esophageal Neoplasms 33Squamous Cell Carcinoma of Head and Neck 31Neuroblastoma 30Lymphoma, Non-Hodgkin 29Colonic Neoplasms 28Small Cell Lung Carcinoma 27Carcinoma, Hepatocellular 27Urethral Neoplasms 25Triple Negative Breast Neoplasms 23

Interventions

olaparib 2tetracarboxyphenylporphine 1testosterone enanthate 1testosterone 17 beta-cypionate 1Testosterone Propionate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Castration-Resistant Prostate Carcinoma × Genitourinary × Clear all
NCT03516812 2025-09-29

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

University of Washington

Phase 2 Completed
36 enrolled 14 charts
Genitourinary

Castration-Resistant Prostate Carcinoma

NCT04951492 2025-01-01

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

University of Washington

Phase 2 Terminated
2 enrolled 9 charts
Genitourinary

Castration-Resistant Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡